Ryan Michael Charles 4
4 · Kiromic Biopharma, Inc. · Filed Aug 2, 2021
Insider Transaction Report
Form 4
Ryan Michael Charles
Chief Technology Officer
Transactions
- Other
Common Stock
2021-07-13+50,189→ 50,189 total - Other
Restricted Stock Units
2021-07-12+31,991→ 31,991 total→ Common Stock (31,991 underlying)
Footnotes (3)
- [F1]The securites were acquired pursuant to a Membership Interest Purchase Agreement dated as of June 14, 2021 among Kiromic Biopharma, Inc., InSilico Solutions, LLC and Michael Ryan.
- [F2]Each restricted stock unit is the economic equivalent of one share of Kiromic Biopharma, Inc. common stock.
- [F3]The vesting schedule is such that 25% of the RSUs vest on June 30, 2022, and the remainder will vest at a rate of 1/36th per month for 36 months thereafter.